A therosclerosis is a chronic inflammatory disease mainly located in branches and bends of the vasculature exposed to disturbed blood flow. Disturbed and oscillatory flows harm the integrity of the vessel wall, 1 resulting in endothelial dysfunction and leading to abnormal endothelial nitric oxide synthase (eNOS) enzymatic activity and vascular inflammation. Conversely, laminar shear stress plays the opposite effect, protecting the endothelial layer, and contributing to release endothelial-derived nitric oxide (NO), adjusting vascular tone, and thus playing protection against inflammation and atherosclerosis. 2 The extensive inducible nitric oxide synthase (iNOS)-mediated NO formation associated with inflammatory cytokine milieu has been linked to the generation of harmful oxidative products and the progression of atherosclerosis. 3 Endothelial cells respond to shear stress by activating cell membrane mechanoreceptors, such as integrins. 4 On ligand binding, integrins cluster and recruit adaptor and signaling proteins to their cytoplasmic domains that mature into large signaling platforms named focal adhesions (FAs), linking extracellular matrix to the actin cytoskeleton. 5 Integrin-linked kinase (ILK), a canonical component of the integrin cell adhesion machinery, binds to eNOS, protects eNOS from uncoupling, and prevents vascular oxidative stress by preventing reactive oxygen species production by uncoupled eNOS. 6 In addition, ILK can regulate eNOS expression.
through Hsp90 (heat shock protein 90) binding. Inhibition of Hsp90 promotes polyubiquitination of ILK by the E3 ligase CHIP (C terminus of HSC70-interacting protein), leading to its proteasomal degradation. 16 We had previously reported the strike correlation between attenuation of ILK and atherosclerosis progression. 6 We, therefore, questioned whether iNOS-derived NO could be involved in ILK-decreased expression during atherosclerosis and vascular remodeling. In the current work, we show that NO released by iNOS decreases ILK levels and induces ILK endocytosis and degradation in the lysosomal compartment ILK. This is a new unidentified pathway mediating endothelial dysfunction in atherosclerotic disease.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

ILK Expression Decreases in Human Atherosclerosis and in a Mouse Model of Vascular Remodeling
Because iNOS-mediated NO formation has been linked to the development of atherosclerosis, 17, 18 ILK and iNOS levels were studied in endarterectomy specimens of human carotid arteries (n=25) showing varying degrees of atherosclerosis (plaque) and in human arterial specimens free of atherosclerosis as controls (healthy, n=20). Confirming our earlier observations, 6 Western blot analysis revealed a significant decrease in total ILK expression in atherosclerotic carotid arteries versus healthy vessels ( Figure 1A ). However, iNOS levels were increased in atherosclerotic vessels compared with healthy arteries, suggesting a link between ILK downregulation and iNOS expression. ILK is expressed at high levels in the endothelium of healthy arteries ( Figure IA in the online-only Data Supplement). However, its endothelial expression is reduced in atherosclerotic arteries ( Figure 1B ). The integrity of the endothelial layer was determined by CD31 staining. iNOS expression was patent in atherosclerotic arteries in disperse foci within the plaque and in the restenotic regions.
To further study the connection between ILK and iNOS protein expression, we examined ILK levels in a mouse model of vascular remodeling by carotid artery ligation (CAL) in wild-type (WT) and iNOS knockout mice ( Figure 1C) . First, ILK levels were studied by confocal microscopy in uninjured (control) group, finding a strong expression of ILK in the smooth muscle layer and a robust signal of ILK at the endothelial layer of normal arteries in both WT and iNOS knockout mice. Thus, indicating that ILK is normally expressed at the healthy endothelium. By contrast, 21-day permanent CAL resulted in a marked decrease of ILK expression in the endothelium in the WT mice group, whereas the iNOS knockout mice still exhibit a clear expression of endothelial ILK, indicating a role for iNOS-derived NO in the reduction of endothelial ILK during vascular remodeling. Confirming our human data, iNOS levels increased in the remodeled WT arteries correlating inversely with ILK levels ( Figure 1D ). To expand these findings, we also studied ILK expression at the protein and mRNA levels. Results in Figure IB in the online-only Data Supplement show that ILK protein expression was reduced in CAL versus control groups in WT mice, whereas ILK did not decrease in iNOS knockout mice in CAL versus control animals. However, mRNA analysis showed no differences in ILK mRNA expression ( Figure IC in the online-only Data Supplement).
iNOS-Derived NO Reduces ILK Content in Endothelial Cells by Decreasing Protein Stability
Intimal inflammation is an early step of atherosclerosis. 19 To test whether inflammation may regulate endothelial ILK expression, we followed the levels of ILK in response to the proinflammatory cytokine TNF-α (tumor necrosis factor α), which induces several proinflammatory genes, including iNOS, in endothelial cells. In mouse aortic endothelial cell (MAEC) stimulated for 24 hours with 100 ng/mL TNF-α, a significant increase of iNOS was detected, together with reduced ILK levels ( Figure 2A, top) , whereas pharmacological inhibition of iNOS activity with 1400W prevented ILK decreased expression in TNF-α-stimulated MAEC. Taken together, our data suggest that inflammation-induced downregulation of ILK is mediated by NO produced by iNOS. Supporting these findings, TNF-α had no effect in iNOS knockout MAEC (Figure 2A, bottom) .
We and other found that decreased ILK led to endothelial dysfunction by eNOS uncoupling. 6, 7, 20 Thus, we tested superoxide levels in MAEC isolated from WT and iNOS knockout mice, finding an increase in superoxide production in TNF-α-treated WT MAEC, which was not observed in iNOS knockout mice ( Figure 2B ). This increase could also be detected in WT MAEC treated with 2 different NO donors ( Figure 2C ), which differ in the timing of NO release. The NO donor-stimulated superoxide formation could be inhibited by the nitric oxide synthase inhibitor L-NAME (L-nitroarginine methyl ester). eNOS expression did not change in either condition, suggesting that exogenous NO and endogenous iNOS-derived NO reduce ILK levels facilitating eNOS uncoupling to produce superoxide anion in endothelial cells.
To further explore the contribution of iNOS-derived NO to eNOS uncoupling, we examined ILK binding to eNOS and Hsp90. Immunoprecipitation of ILK from WT MAEC lysates detected coprecipitation with eNOS and Hsp90 in control cells, whereas NO donor treatment or iNOS induction reduced the levels of both proteins in ILK immunoprecipitates ( Figure 2D ). ILK forms a complex termed IPP (ILK, parvin, PINCH complex, which includes PINCH/α-parvin) 21 and the FA protein paxillin 22 that is an essential element in integrin signaling. Thus, we explored the stability of the IPP complex in the presence of NO. Immunoprecipitation of ILK in protein lysates from MAEC treated with different NO donors revealed a significant reduction in the binding to α-parvin and paxillin. In contrast, PINCH association with ILK was slightly affected by NO ( Figure 3A ). In addition, immunoblot of protein lysates from 10 −5 to 10 −7 mol/L spermidine-NOnoate (SP-NO)-treated MAEC showed a marked decrease of paxillin and α-parvin levels in a dose-response manner while PINCH was reduced at the highest concentration of NO ( Figure 3B ). In addition, we analyzed ILK enzymatic activity detected as phosphorylation of its downstream mediator GSK3-β (glycogen synthase kinase 3 beta), finding that NO decreases GSK3-β phosphorylation by ILK ( Figure 3C ).
NO Induces ILK Ubiquitination and Leads to ILK Degradation in the Lysosome
Next, to investigate the molecular mechanism of NO-mediated modulation of ILK, mRNA and protein levels of ILK were analyzed in MAEC incubated with 10 −5 mol/L SP-NO for 0 to 24 hours, finding that rather than a transcriptional effect ( Figure Data Supplement), indicating that NO promotes a post-transcriptional modification of ILK.
To further assess the role of NO on ILK-decreased protein levels, cycloheximide was used to block de novo protein synthesis in MAEC. As shown in Figure IIC in the online-only Data Supplement, ILK decay rate was slow in cycloheximidetreated cells because a 20±0.5% of ILK was reduced 24 hours after treatment with 50 µmol/L cycloheximide while in MAEC coincubated with 50 µmol/L cycloheximide+10 −5 mol/L SP-NO, ILK half-life was shortened by a 70±1%.
Because NO disrupts ILK-Hsp90 interaction ( Figure 2D ) and Hsp90 prevents ILK degradation by the proteasome, 23 we addressed whether NO induces ILK ubiquitination. Protein lysates from NO-treated MAEC were immunoprecipitated with antiubiquitin and anti-ILK-specific antibodies. ILK immunoprecipitation revealed a significant increase of ubiquitinated ILK in SP-NO-treated MAEC ( Figure 4A, top) , and conversely ubiquitinated extracts contained significant levels of ILK in the same cells ( Figure 4A, bottom) . In human atherosclerotic protein lysates, in which we previously found a significant increase of iNOS ( Figure 1A) , ILK immunoprecipitates also revealed extensive ubiquitination ( Figure IIIA in the online-only Data Supplement), suggesting that NO may play a role on ILK ubiquitination.
ILK ubiquitination can be accomplished by the E3 ubiquitin ligase CHIP, driving its degradation by the proteasome. 19 We could detect a significant increase of the complex CHIP/ILK in SP-NO-treated MAEC ( Figure IIIB in the online-only Data Supplement). Next, we measured ILK levels in MAEC transfected with CHIP small interfering RNA or scrambled small interfering RNA as control. In small interfering RNA control, but not in CHIP-silenced cells, NO reduced ILK levels ( Figure  IIIC did not block the NO-induced degradation of ILK. Interestingly, they potentiated the inhibitory effect of NO ( Figure 4C ). NO did not increase proteasome activity and MG-132, accurately inhibited proteasome activity as expected ( Figure IIID in the onlineonly Data Supplement), suggesting that the proteasome pathway may not contribute to ILK degradation in response to NO.
Ubiquitinated proteins can be cleared from the cells by the proteasome and alternatively by lysosome-mediated degradation or by the autophagy pathway. 24 Pre-treatment of MAEC with the lysosomal inhibitor chloroquine (10 µmol/L) reversed the effect of NO on ILK levels ( Figure 4C ). To go deeply into the mechanism, we found that ILK was mainly located at the cell surface in resting MAEC ( Figure 4D, control) . In contrast, ILK was internalized into discrete vesicles and colocalized with the lysosomal marker LAMP-1 in response to 10 Taken together, our results indicate that NO induces CHIP-mediated ILK ubiquitination, but neither the proteasome nor the autophagy plays a role in the regulation of ILK by NO. NO, on the contrary, induces the lysosomal-dependent degradation of ILK.
NO Triggers ILK Endocytosis Through a Dynamin-Dependent Pathway
A key step in protein trafficking from the plasma membrane to specific intracellular compartments is internalization in endocytic vesicles. 26 Thus, we sought to investigate whether NO Endocytosis of integrins and associated proteins can be accomplished by chlatrin-dependent, caveolae-dependent, and noncaveolae-mediated pathways. [27] [28] [29] The first 2 processes rely on the GTPase dynamin for the scission of endocytic intermediates to generate early endosomes. 30 Previous studies have demonstrated that NO can stimulate endocytosis by S-nytrosilation of dynamin. 31 ,32 Therefore, we tested whether dynamin-mediated endocytosis was involved in NO-induced ILK degradation by using a specific inhibitor of dynamin activity, Dyngo 4a. Confocal microscopy showed that dynamin was mediating the NO-dependent internalization of ILK into endosomes. Dyngo 4a prevented ILK localization in vesicles containing the early endosome marker EEA1 observed after 30-minute treatment with the NO donor ( Figure 5A ). Conversely, ILK localization in lysosomes after 6-hour treatment with the NO donor was prevented by Dyngo 4a. Accordingly, Dyngo 4a reversed the increased degradation of ILK induced by NO ( Figure 5B ). In fact, Dyngo 4a restored NO inhibitory effect on ILK enzymatic activity ( Figure 5C ). These results demonstrate that NO-induced ILK internalization and degradation in lysosomes are mediated by a dynamin-dependent mechanism.
Discussion
The data presented in this article show that iNOS-derived NO plays a crucial role during atherosclerosis by regulating the endocytic-lysosomal degradation of ILK in endothelial cells. NO-mediated ILK degradation is described here for the first time, through a dynamin-depend endocytosis that drives ILK to a lysosome degradative pathway. Our results shed light about the molecular mechanisms by which inflammatory NO contributes to endothelial dysfunction and provide with a new target to fight against atherosclerosis. We previously found an inverse correlation between progression of atherosclerosis and the levels of ILK in the vessel wall. Here, we also found an association between ILK decrease and iNOS induction in atherosclerotic arteries. A key early step in the progression of atherosclerosis involves endothelial damage, adhesion of oxidized low-density lipoprotein to the vascular endothelium, and infiltration of inflammatory leukocytes. Endothelial dysfunction perpetuates impaired NO production and initiate an inflammatory reaction in the vessel wall which lead to extensive NO/iNOS production, proinflammatory cytokine activation, extracellular matrix degradation, smooth muscle cell migration, increased reactive oxygen and nitrogen species, endothelial and VSMC (vascular smooth muscle cells) necrosis, apoptosis, and accumulation of cellular debris, leading to plaque formation. 33 We provide molecular evidence about the mechanisms that lead to iNOS-induced endothelial cell dysfunction, by promoting endocytosis and lysosomal degradation of ILK. We previously demonstrated that eNOS form a complex with Hsp90/ILK to regulate vascular tone. In the absence of ILK, uncoupled eNOS switch to produce reactive oxygen species, leading to cellular damage. 6 Our data show that iNOS-NO lead to eNOS uncoupling by decreasing ILK and disrupting eNOS-Hsp90-ILK interaction. We propose that preventing ILK-mediated degradation could represent a new target against atherosclerosis. In support of this hypothesis, ILK prevents endothelial cells apoptosis induced by oxidized lowdensity lipoprotein, 34 and restoring the levels of ILK can rescue the repairing activities of endothelial progenitor cells. 20, 35 In a model of vascular remodeling by CAL, we observed that ILK was decreased in the vascular wall in WT mice after carotid ligation compared with the levels found in iNOS knockout animals, indicating that inducible NO regulates the levels of ILK during the process of remodeling. In agreement with these findings, downregulation of ILK after myocardial infarction caused impairment of angiogenesis, angiogenic dysfunction, and myocyte cell loss. 36 By contrast, sustained expression of ILK by adenoviral delivery could effectively promote angiogenesis and preserve heart function. Other models of neointimal formation have reported similar results, including balloon catheter carotid injury, where a decrease in ILK has been reported at the media layer, and re-expression at the luminal surface may attenuate this process during later stages of the injury response. 13 Additional examples include ablation of ILK in cultured endothelial cells, resulting in defective cell spreading, or progenitor endothelial cells lacking ILK which lead to defective vasculogenesis and embryonic lethality between E8.5 and E12.5, 37 whereas, in the adult, the absence of ILK produced endothelial dysfunction. 6 Despite the relevant role of ILK in the cardiovascular system, the mechanism of ILK stability has not been studied in detail. It is being reported that Hsp90 binds to ILK at the kinase homology domain, preventing ILK proteasomal degradation, thus we hypothesized that NO would increase ILK ubiquitination and proteasomal degradation, by promoting the disruption of the complex Hsp90/ILK. However, our results showed that even when ILK was effectively ubiquitinated in presence of NO and during atherosclerosis, proteasome inhibitors did not reverse such effect, rather potentiated the effect of NO. We might argue that NO could modulate the ubiquitin/proteasome system, as previously reported, 38 but NO had no effect in this work, concluding that the decrease in ILK stability induced by NO was not dependent on the proteasome pathway. Others found that NO regulates the expression of ILK in kidney cells, 39 but as today, our work provides the first molecular evidence about the post-transcriptional effect of NO on ILK protein stability.
What is the mechanism responsible of ILK ubiquitination? It is known that inhibition of Hsp90 promotes ILK ubiquitination by CHIP, which drives ILK to proteasome degradation. 16 CHIP acts not only as a E3 ubiquitin ligase but also as a protein chaperone linking Hsp90 to ILK. CHIP seems to be a key step in the degradative road, as demonstrated in CHIPsilenced cell, in which ILK degradation induced by NO was partially reversed. One explanation is that NO targets Hsp90 to disrupt CHIP-ILK interaction. Hsp90 plays a critical role in ILK stability and signaling, it protects ILK from protein degradation and promotes ILK complex with α-parvin and the cytoskeleton, 23 and we found that Hsp90-ILK interaction is necessary to prevent endothelial nitric oxide synthase enzymatic uncoupling that leads to endothelial dysfunction. It is accepted that S-nitrosylation of Hsp90 inhibits Hsp90 chaperone and ATPase activities 40 required to bind ILK to α-parvin and paxillin. So, S-nitrosylation of Hps90 could also support the loss of α-parvin and paxillin from the complex in NO-treated MAEC, which could explain how increasing amounts of NO contribute to vascular remodeling and also inhibit vascular relaxation. Alternatively, NO may modify ILK by tyrosine nitration to promote protein destabilization. 38 ILK protein contains several tyrosine residues in its pseudokinase domain, which is involved in ILK interaction with Hsp90 and α-parvin. 41 Thus, we cannot exclude that NO effects may be mediated at least, in part, by protein nitration of ILK.
ILK form a ternary complex known as the IPP. The formation of the IPP complex is crucial for the stability of the 3 proteins and is a pre-requisite for them to locate to the cellextracellular matrix adhesion sites. Mutations in PINCH, ILK, or parvin that disrupt the formation of the complex will prevent the other members from locating to FAs 21, 41 and promote their internalization or eventually degradation. Accordingly, our results show that NO was able to destabilize the IPP complex and drive ILK and parvin to lysosomes while it only had a slight effect over PINCH. Paxillin, another FA protein that also interacts with ILK to localize at the FAs, 41 was also detected in lysosomes after NO stimulation. In addition, phosphorylation of ILK target GSK3β was reduced in the presence of NO. Thus, NO acts as a molecular disruptor of endothelial ILK signaling platform during atherosclerosis and vascular remodeling.
Mechanistically, our results show that lysosomal inhibition reversed the effect of NO, describing a colocalization of ILK with the lysosome marker LAMP-1 in cells coincubated with NO and potentiated by the proteasome inhibitor MG-132, proving that ILK is degraded in the lysosome compartment. Autophagy is a process that involves the packaging of cytoplasmic proteins or organelles into vesicles and fused to the lysosome to form an autophagosome. Autophagy plays an important role during atherosclerosis progression. NO can induce autophagy lysosome-mediated claudin-5 degradation in oxygen-glucose deprivation-treated endothelial cells. 42 However, we found here that NO does not induced autophagy at the time and dose used in our study.
Endocytic trafficking has emerged as a critical mechanism for controlling the length and strength of signals via sorting of internalized receptors and their associated signaling complexes for recycling or lysosomal degradation. 43 Several reports demonstrate a role for NO in clathrin-and dynaminmediated endocytosis and also integrins can be endocytosed by these pathways. [27] [28] [29] 44 NO S-nitrosylates dynamin increasing dynamin oligomerization and GTPase activity, thereby increasing endocytosis. 33 Our results support a role for dynamin in ILK internalization because a specific inhibitor of dynamin activation reversed ILK degradation and localization in endosomes and later in lysosomes, thus proving that NO drives ILK endocytosis to direct ILK to lysosome degradation.
In summary, ILK is a key mechanosensitive protein that regulates heart contractility, vascular remodeling, and endothelial cell homeostasis regulating endothelial NO production. We provide for the first time molecular evidence about the negative effect of NO/iNOS on ILK stability by inducing internalization and molecular degradation of ILK in lysosomes (summarized in Figure V in the online-only Data Supplement). This work opens a new target for intervention reversing or stabilizing arterial remodeling by preventing ILK degradation by NO and represents a promising approach for both prevention and treatment of cardiovascular complications caused by hypertension and atherosclerosis in which uncoupling of eNOS leads to impaired NO-dependent vessel relaxation.
